Login to Your Account

ACR Roundup

Tuesday, November 8, 2011

The following data were presented at the American College of Rheumatology (ACR) and the Association of Rheumatology Health Professionals meeting in Chicago.

• 4SC AG, of Planegg-Martinsried, Germany, presented final results from its Phase IIb COMPONENT study that demonstrated substantial anti-inflammatory activity of vidofludimus in rheumatoid arthritis. The international, multicenter, randomized study evaluated the efficacy of vidofludimus in combination with methotrexate (MTX) compared with MTX alone.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription